From the Research
I believe "spratoavo" is likely a misspelling of "Spravato", which is a brand name for the medication esketamine, used for treatment-resistant depression. This medication has been shown to have a favorable risk-to-benefit profile, with demonstrated efficacy in reducing depressive symptoms more rapidly than monotherapy with traditional oral antidepressants 1. The correct spelling and context are crucial in providing accurate information about medications or treatments. If you're seeking medical advice about a specific medication, I recommend consulting with a healthcare provider who can provide personalized guidance based on your specific health needs. Some key points to consider about Spravato (esketamine) include:
- It is an intranasal antidepressant approved by the FDA for management of treatment-resistant depression (TRD) in patients with inadequate response to traditional antidepressant therapy 1
- It is self-administered under the supervision of a healthcare provider and is used as an adjunct to oral antidepressant therapy
- Patients are supervised for 2 hours after self-administering the medication to monitor for sedation, dizziness, dissociation reactions, and increased blood pressure
- Esketamine has demonstrated efficacy in reducing depressive symptoms more rapidly than monotherapy with traditional oral antidepressants, with a favorable risk-to-benefit profile 1